Lupin acquires five brands from Menarini
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
The strategic appointment is also critical to reinforcing Healthium’s market leadership, corporate governance and deep domain expertis
The appointment is effective from May 01, 2023 for five years
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Subscribe To Our Newsletter & Stay Updated